D. Maggs

C. Weyer, M. Fineman, D. Maggs, 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Diabetes Care

A. Skene, M. Massi-Benedetti, J. Northrup, 1995, Medical economics.

Effect of insulin on glycerol production in obese adolescents.

G. Shulman, D. Silver, S. Caprio, 1998, The American journal of physiology.

Effect of insulin on glycerol production in obese adolescents.

G. Shulman, D. Silver, W. Tamborlane, 1998, American journal of physiology. Endocrinology and metabolism.

Counterregulation in Peripheral Tissues: Effect of Systemic Hypoglycemia on Levels of Substrates and Catecholamines in Human Skeletal Muscle and Adipose Tissue

W. Tamborlane, S. Caprio, R. Sherwin, 1997, Diabetes.

Metabolic heat production and cardiovascular responses to an incremental intravenous infusion of adrenaline in healthy subjects

I. Macdonald, D. Maggs, K. Fone, 1994, Clinical Autonomic Research.

Peptide-based GIP receptor inhibition exhibits modest metabolic changes in mice when administered either alone or combined with GLP-1 agonism

Soumitra S Ghosh, Harith Rajagopalan, J. West, 2020 .

Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes

G. Costamagna, J. Devière, D. Maggs, 2018, Digestive Diseases.

Insulin-like Growth Factor-1 and the Endocrine Pancreas

R. Sherwin, D. Maggs, 2011 .

The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity.

W. Tamborlane, S. Caprio, R. Sherwin, 1998, The Journal of clinical endocrinology and metabolism.

Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations.

D. Silver, W. Tamborlane, S. Caprio, 1996, The American journal of physiology.

Does Ethanol Cause Hypoglycaemia in Overnight Fasted Patients with Type 1 Diabetes?

I. Macdonald, R. Tattersall, D. Maggs, 1993, Diabetic medicine : a journal of the British Diabetic Association.

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.

D. Kendall, D. Maggs, A. Stonehouse, 2008, Current diabetes reviews.

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

C. Weyer, M. Fineman, J. Ruggles, 2002, Diabetes care.

The adipose tissue/central nervous system axis

M. Lane, T. Loftus, D. Maggs, 1997, Diabetologia.

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

C. Weyer, A. Young, D. Maggs, 2001, Current pharmaceutical design.

Is insulin the most effective injectable antihyperglycaemic therapy?

J. Buse, A. Peters, D. Russell-Jones, 2015, Diabetes, obesity & metabolism.

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

G. Shulman, S. Inzucchi, D. Maggs, 1998, The New England journal of medicine.

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Yan Wang, Christian Weyer, Claresa Levetan, 2003, Diabetes care.

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

S. Paul, J. Best, D. Maggs, 2016, Journal of diabetes.

Chapter 30 – Beyond Insulin Therapy

D. Maggs, J. Crean, 2006 .

Microdialysis techniques in the study of brain and skeletal muscle

R. Sherwin, D. Maggs, W. Borg, 1997, Diabetologia.

Striking Differences in Glucose and Lactate Levels between Brain Extracellular Fluid and Plasma in Conscious Human Subjects: Effects of Hyperglycemia and Hypoglycemia

D. Spencer, J. Krystal, T. Jones, 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Hormone-based therapies in the regulation of fuel metabolism and body weight

D. Maggs, J. Roth, N. Kesty, 2008, Expert opinion on biological therapy.

Incretin-based therapies

T. Darsow, D. Maggs, A. Stonehouse, 2012, Journal of diabetes.

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Dennis D. Kim, D. Maggs, R. Brodows, 2006, Diabetes, obesity & metabolism.

Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle.

W. Tamborlane, R. Sherwin, D. Maggs, 1995, The Journal of clinical investigation.

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

R. DeFronzo, M. Abdul-Ghani, C. Triplitt, 2015, Diabetes, obesity & metabolism.

Cardiovascular outcomes associated with a new once‐weekly GLP‐1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis

K. Boye, D. Maggs, J. Gaebler, 2011, Diabetes, obesity & metabolism.

Proximal and Distal Gut Mucosa Adapt Differently to Westernized Diet, Promoting an Insulin-Resistant Dysmetabolic State

Soumitra S Ghosh, Harith Rajagopalan, J. West, 2019, bioRxiv.

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

M. Trautmann, C. Wysham, D. Maggs, 2015, Mayo Clinic proceedings.

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

M. S. Lewis, R. DeFronzo, Y. Qu, 2010, Diabetes Care.

Hydrothermal Duodenal Mucosal Resurfacing: Role in the Treatment of Metabolic Disease.

J. Devière, Harith Rajagopalan, A. Cherrington, 2017, Gastrointestinal endoscopy clinics of North America.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years*

D. Klonoff, J. Buse, D. Maggs, 2008 .

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

D. Klonoff, J. Buse, D. Maggs, 2007, Clinical therapeutics.

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

K. Klein, S. Paul, J. Best, 2015, Cardiovascular Diabetology.

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

Soumitra S Ghosh, Harith Rajagopalan, J. West, 2021, PloS one.

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

D. Maggs, R. Pencek, Yan Li, 2013, Diabetes, metabolic syndrome and obesity : targets and therapy.

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide *

K. Klein, S. Paul, J. Best, 2012, Diabetes, obesity & metabolism.

Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

T. Buchanan, G. Shulman, K. Polonsky, 1998, Annals of Internal Medicine.

Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes

M. Nauck, D. Maggs, D. Maggs, 2007, Diabetes, obesity & metabolism.

Diabetes mellitus and gastric emptying: questions and issues in clinical practice

A. Vella, B. Göke, M. Samsom, 2009, Diabetes/metabolism research and reviews.

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

C. Weyer, M. Fineman, D. Maggs, 2003, Diabetes care.

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy

J. Buse, C. Weyer, D. Maggs, 2002 .

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials

S. Brunell, D. Maggs, Yan Li, 2016, Advances in Therapy.

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

J. Frias, S. Edelman, D. Maggs, 2013, Postgraduate medicine.

Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素

K. Klein, S. Paul, J. Best, 2015, Journal of diabetes.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Dennis D. Kim, C. Weyer, S. Schwartz, 2003, Diabetes care.

Is the metabolic syndrome a real clinical entity and should it receive drug treatment?

D. Kendall, T. Darsow, D. Maggs, 2006, Current diabetes reports.

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

C. Weyer, M. Fineman, D. Maggs, 2003, Diabetes, obesity & metabolism.

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Gerardo Soto-Campos, Amy Blickensderfer, Marc Cohen, 2012, Vascular health and risk management.

GLP‐1 based therapies: differential effects on fasting and postprandial glucose

M. Fineman, B. Cirincione, M. Diamant, 2012, Diabetes, obesity & metabolism.

K. Klein, S. Paul, J. Best, 2015, Journal of diabetes.

Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study

R. DeFronzo, M. Abdul-Ghani, C. Triplitt, 2018, Diabetes.

Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.

L. Heinemann, S. Heller, T. Heise, 2004, Metabolism: clinical and experimental.

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin‐induced hypoglycaemia in patients with type 1 diabetes

I. Macdonald, S. Heller, S. Amiel, 2005, Diabetes, obesity & metabolism.